Inverness Counsel’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $849K | Buy |
19,406
+800
| +4% | +$38.9K | 0.05% | 94 |
|
|
2022
Q2 | $976K | Buy |
18,606
+502
| +3% | +$25.6K | 0.05% | 78 |
|
|
2022
Q1 | $937K | Sell |
18,104
-1,997
| -10% | -$104K | 0.04% | 91 |
|
|
2021
Q4 | $1.19M | Sell |
20,101
-2,089
| -9% | -$104K | 0.04% | 77 |
|
|
2021
Q3 | $954K | Sell |
22,190
-700
| -3% | -$31K | 0.04% | 92 |
|
|
2021
Q2 | $896K | Sell |
22,890
-2,140
| -9% | -$83.2K | 0.03% | 94 |
|
|
2021
Q1 | $907K | Sell |
25,030
-2,050
| -8% | -$72.8K | 0.04% | 89 |
|
|
2020
Q4 | $997K | Sell |
27,080
-3,127
| -10% | -$115K | 0.04% | 84 |
|
|
2020
Q3 | $1.05M | Hold |
30,207
| – | – | 0.05% | 77 |
|
|
2020
Q2 | $937K | Sell |
30,207
-1,913
| -6% | -$65K | 0.05% | 79 |
|
|
2020
Q1 | $995K | Sell |
32,120
-1,056
| -3% | -$36K | 0.06% | 72 |
|
|
2019
Q4 | $1.23M | Sell |
33,176
-52
| -0.2% | -$1.85K | 0.06% | 78 |
|
|
2019
Q3 | $1.13M | Sell |
33,228
-2,475
| -7% | -$90K | 0.06% | 74 |
|
|
2019
Q2 | $1.47M | Sell |
35,703
-4,098
| -10% | -$163K | 0.07% | 68 |
|
|
2019
Q1 | $1.6M | Sell |
39,801
-4,559
| -10% | -$183K | 0.09% | 66 |
|
|
2018
Q4 | $1.84M | Sell |
44,360
-625
| -1% | -$25.9K | 0.12% | 61 |
|
|
2018
Q3 | $1.88M | Buy |
44,985
+795
| +2% | +$30.6K | 0.1% | 66 |
|
|
2018
Q2 | $1.52M | Sell |
44,190
-2,992
| -6% | -$102K | 0.09% | 68 |
|
|
2018
Q1 | $1.59M | Buy |
47,182
+4,671
| +11% | +$161K | 0.1% | 74 |
|
|
2017
Q4 | $1.46M | Sell |
42,511
-9,939
| -19% | -$339K | 0.09% | 68 |
|
|
2017
Q3 | $1.78M | Sell |
52,450
-11,043
| -17% | -$355K | 0.13% | 62 |
|
|
2017
Q2 | $2.02M | Sell |
63,493
-10,176
| -14% | -$321K | 0.14% | 61 |
|
|
2017
Q1 | $2.37M | Sell |
73,669
-346,295
| -82% | -$10.9M | 0.17% | 60 |
|
|
2016
Q4 | $12.6M | Buy |
419,964
+81,014
| +24% | +$2.47M | 0.95% | 39 |
|
|
2016
Q3 | $10.9M | Buy |
338,950
+316,243
| +1,393% | +$10.6M | 0.86% | 37 |
|
|
2016
Q2 | $759K | Buy |
22,707
+3,076
| +16% | +$98.2K | 0.06% | 70 |
|
|
2016
Q1 | $552K | Sell |
19,631
-738
| -4% | -$21.1K | 0.04% | 72 |
|
|
2015
Q4 | $624K | Sell |
20,369
-1,106
| -5% | -$34.8K | 0.05% | 73 |
|
|
2015
Q3 | $640K | Sell |
21,475
-335
| -2% | -$10.7K | 0.05% | 75 |
|
|
2015
Q2 | $694K | Hold |
21,810
| – | – | 0.05% | 78 |
|
|
2015
Q1 | $720K | Sell |
21,810
-8,605
| -28% | -$274K | 0.05% | 79 |
|
|
2014
Q4 | $899K | Buy |
30,415
+3,289
| +12% | +$94.3K | 0.07% | 77 |
|
|
2014
Q3 | $761K | Buy |
27,126
+1,097
| +4% | +$30.8K | 0.06% | 79 |
|
|
2014
Q2 | $733K | Sell |
26,029
-1,581
| -6% | -$45.1K | 0.06% | 79 |
|
|
2014
Q1 | $841K | Buy |
27,610
+686
| +3% | +$20.5K | 0.07% | 74 |
|
|
2013
Q4 | $782K | Sell |
26,924
-2,472
| -8% | -$71.9K | 0.06% | 80 |
|
|
2013
Q3 | $801K | Buy |
29,396
+527
| +2% | +$14.3K | 0.07% | 74 |
|
|
2013
Q2 | $767K | Buy |
+28,869
| New | +$798K | 0.07% | 70 |
|
Other funds holding PFE
Inverness Counsel's PFE Position: Q3 2022 in Review
Inverness Counsel increased its Pfizer (PFE) stake by 4.3% in Q3 2022, buying an estimated $38.9K and bringing the position to 19,406 shares worth $849K. The position accounts for 0.05% of the portfolio, ranked #94.
Inverness Counsel first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $12.6M in Q4 2016. 3,087 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- Inverness Counsel held 19,406 shares of Pfizer worth $849K as of Q3 2022.
- Inverness Counsel bought 800 Pfizer shares in Q3 2022, an estimated $38.9K.
- Pfizer made up 0.05% of Inverness Counsel's portfolio in Q3 2022, its #94 holding.
- Inverness Counsel first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- Inverness Counsel's Pfizer position peaked at $12.6M in Q4 2016.
- 3,087 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.